Kashiwagi T, Yan H, Hamasaki T, Kinjo T, Nakamichi N, Teruya K
Oxid Med Cell Longev. 2014; 2014:869121.
PMID: 25383141
PMC: 4212634.
DOI: 10.1155/2014/869121.
Momparler R
Pharmaceuticals (Basel). 2013; 5(8):875-81.
PMID: 24280679
PMC: 3763670.
DOI: 10.3390/ph5080875.
Karahoca M, Momparler R
Clin Epigenetics. 2013; 5(1):3.
PMID: 23369223
PMC: 3570332.
DOI: 10.1186/1868-7083-5-3.
Come M, Skladanowski A, Larsen A, Laurent G
Br J Cancer. 1999; 79(7-8):1090-7.
PMID: 10098741
PMC: 2362243.
DOI: 10.1038/sj.bjc.6690174.
Sorensen M, Sehested M, Christensen I, Larsen J, Jensen P
Br J Cancer. 1998; 77(12):2152-61.
PMID: 9649127
PMC: 2150415.
DOI: 10.1038/bjc.1998.360.
A novel mutation in DNA topoisomerase I of yeast causes DNA damage and RAD9-dependent cell cycle arrest.
Levin N, Bjornsti M, Fink G
Genetics. 1993; 133(4):799-814.
PMID: 8385050
PMC: 1205401.
DOI: 10.1093/genetics/133.4.799.
Effects of selected chemotherapeutic agents on PCNA expression in prostate carcinoma cell lines.
Qiao L, Pizzolo G, Melamed M
Urol Res. 1994; 22(3):171-76.
PMID: 7992463
DOI: 10.1007/BF00571846.
Experimental investigations on a sequential combination chemotherapy protocol.
Klein H, Toermer H, Christian E, COERPER C, LENNARTZ K, AKOKAN G
J Cancer Res Clin Oncol. 1980; 96(1):65-78.
PMID: 7358773
DOI: 10.1007/BF00412898.
The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.
McGown A, Poppitt D, Swindell R, Fox B
Cancer Chemother Pharmacol. 1984; 13(1):47-53.
PMID: 6733842
DOI: 10.1007/BF00401447.
The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.
Wheeler R, Clauw D, Natale R, Ruddon R
Invest New Drugs. 1983; 1(4):283-95.
PMID: 6432722
DOI: 10.1007/BF00177411.
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.
Momparler R, Samson J, Momparler L, Rivard G
Cancer Chemother Pharmacol. 1984; 13(3):191-4.
PMID: 6207950
DOI: 10.1007/BF00269027.
Localization of the labelled 5-azacytidine in cultured mouse embryonic cells.
Seifertova M, Vesely J, CIHAK A
Experientia. 1974; 30(12):1463-5.
PMID: 4442554
DOI: 10.1007/BF01919696.
Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks.
Avemann K, Knippers R, Koller T, Sogo J
Mol Cell Biol. 1988; 8(8):3026-34.
PMID: 2850477
PMC: 363528.
DOI: 10.1128/mcb.8.8.3026-3034.1988.
Mathematical analysis of cancer chemotherapy.
Chuang S, Lloyd H
Bull Math Biol. 1975; 37(2):147-60.
PMID: 1156695
DOI: 10.1007/BF02470621.
Early responses to chemotherapy detected by pulse cytophotometry.
Smets L, Mulder E, de Waal F, Cleton F, Blok J
Br J Cancer. 1976; 34(2):153-61.
PMID: 989466
PMC: 2025166.
DOI: 10.1038/bjc.1976.137.
Mathematical analysis of cancer chemotherapy: the effects of chemotherapeutic agents on the cell cycle traverse.
Chuang S, Soong T
Bull Math Biol. 1978; 40(4):499-512.
PMID: 678695
DOI: 10.1007/BF02460774.
A quantitative approach to the design of antitumor drug dosage schedule via cell cycle kinetics and systems theory.
Kim M, Woo K, Perry S
Ann Biomed Eng. 1977; 5(1):12-33.
PMID: 557938
DOI: 10.1007/BF02409336.
